The molecular basis of spinocerebellar ataxia type 48 caused by a de novo mutation in the ubiquitin ligase CHIP

The spinocerebellar ataxias (SCAs) are a class of incurable diseases characterized by degeneration of the cerebellum that results in movement disorder. Recently, a new heritable form of SCA, spinocerebellar ataxia type 48 (SCA48), was attributed to dominant mutations in STIP1 homology and U box-containing 1 (STUB1); however, little is known about how these mutations cause SCA48. STUB1 encodes for the protein C terminus of Hsc70 interacting protein (CHIP), an E3 ubiquitin ligase. CHIP is known to regulate proteostasis by recruiting chaperones via a N-terminal tetratricopeptide repeat domain and recruiting E2 ubiquitin-conjugating enzymes via a C-terminal U-box domain. These interactions allow CHIP to mediate the ubiquitination of chaperone-bound, misfolded proteins to promote their degradation via the proteasome. Here we have identified a novel, de novo mutation in STUB1 in a patient with SCA48 encoding for an A52G point mutation in the tetratricopeptide repeat domain of CHIP. Utilizing an array of biophysical, biochemical, and cellular assays, we demonstrate that the CHIP^A52G point mutant retains E3-ligase activity but has decreased affinity for chaperones. We further show that this mutant decreases cellular fitness in response to certain cellular stressors and induces neurodegeneration in a transgenic Caenorhabditis elegans model of SCA48. Together, our data identify the A52G mutant as a cause of SCA48 and provide molecular insight into how mutations in STUB1 cause SCA48.     

陕北白绒山羊DRB1基因外显子2遗传变异分析

本研究通过对123只陕北白绒山羊DRB1基因外显子2的遗传变异分析,旨在获得陕北白绒山羊DRB1基因的多态性及变异信息,为山羊抗病基因的挖掘研究提供基础资料。本研究共获得6条陕北白绒山羊DRB1基因外显子2序列,其中4条为首次发现。生物信息学分析表明DRB1位点具有较高的多态性,6条等位基因可能起源于2个祖先基因。在长期的进化过程中,DRB1位点受到了明显的选择压力作用,这种选择作用有助于陕北白绒山羊对当地气候的适应。蛋白质结构的预测证实了DRB1*1与其它等位基因间的差异性,说明核苷酸变异可能会引起蛋白质结构的改变,最终可能影响宿主对病原体的免疫应答。本次对陕北白绒山羊DRB1基因多态性的调查与分析有助于筛选疾病抗性和易感性MHC (Major histocompatibility complex)候选基因,进而可加速绒山羊抗病品系的改良与培育进程。     

From signaling to function: how strigolactones regulate plant development

Science China Life Sciences -     

Ultrasensitive Deep-Ultraviolet Surface Plasmon Resonance Sensors Using Aluminum-Graphene Metasurface: a Theoretical Insight

Plasmonics - This study investigates a versatile deep-ultraviolet (DUV) surface plasmon resonance (SPR) sensor by integrating a few graphene layers into low-cost aluminum (Al) thin film. The...     

Aidi injection,a traditional Chinese biomedical preparation for gynecologic tumors: a systematic review and PRISMA-compliant meta-analysis

Aidi injection (ADI), a traditional Chinese biomedical preparation, is a promising adjuvant therapy for gynecologic tumors (GTs), including cervical cancer (CC), endometrial cancer (EC), and ovarian cancer (OC). Although studies have reported positively on ADI therapy, its exact effects and safety in GT patients remain controversial. Therefore, a wide-ranging systematic search of electronic databases was performed for this meta-analysis. Data from 38 trials including 3309 GT patients were analyzed. The results indicated that the combination of conventional treatment and ADI markedly improved the patients’ overall response rate (P<0.00001), disease control rate (P<0.00001), and quality of life (P<0.05) compared with conventional treatment alone. Furthermore, patient immunity was enhanced with combined treatment, as indicated by significantly increased percentages of CD3⁺ (P=0.005) and CD4⁺ (P<0.00001) and increased CD4⁺/CD8⁺ ratio (P=0.001). Most of the adverse events caused by radiochemotherapy such as gastrointestinal issues, leukopenia, thrombocytopenia, and hepatotoxicity, (P<0.05 for all) were significantly alleviated when ADI was used in the GT patients. However, other adverse events such as nephrotoxicity, diarrhea, alopecia, and neurotoxicity did not significantly differ between the two groups. Overall, these results suggest that the combination of conventional and ADI treatment is more effective than conventional treatment alone.